The Wegovy Launch in the UK: A Timeline of What Changed

Step 1: The original UK approval and first patient access (2023)

Semaglutide at the 2.4 mg weekly maintenance dose had been authorised by the MHRA for weight management before its commercial launch in the UK in September 2023. The licence covers adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as hypertension, high cholesterol or obstructive sleep apnoea, used alongside a reduced-calorie diet and increased physical activity.

The evidence behind the original approval was substantial. The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks and found an average weight reduction of around 15% at the 2.4 mg dose. That figure came from a randomised, placebo-controlled study, not a manufacturer estimate.

In March 2023, NICE published its recommendation (TA875) for semaglutide on the NHS, but with strict conditions: a maximum treatment duration of two years, use within a specialist weight management service with multidisciplinary support, and a BMI of 35 or above alongside at least one comorbidity. For many adults who met the licensed criteria but not the NICE NHS threshold, private prescribing became the practical route. The injection starts at 0.25 mg weekly and is titrated by the prescriber through several steps before reaching the 2.4 mg maintenance dose.

If you want a fuller picture of how semaglutide's launch date shaped the treatment landscape before the current options became available, that page covers the background in detail, and the Wegovy overview at nume covers the current treatment in detail.

Step 2: The 7.2 mg dose and the single-dose pen (early 2026)

The story didn't stop at 2.4 mg. In January 2026, the MHRA approved semaglutide at a higher maintenance dose of 7.2 mg weekly for adults with a BMI of 30 or above. At that point it was supplied as three separate 2.4 mg pens used in a single week, which was a workable but inelegant solution.

On 14 April 2026 the MHRA approved a dedicated single-dose 7.2 mg pen, one pre-set weekly injection, with an auto-dosing mechanism, a covered needle and a lock after use. Trials at the 7.2 mg dose reported an average weight loss of around 20.7% over 72 weeks, closing the gap noticeably with tirzepatide at its highest licensed dose. The 7.2 mg pen is licensed for obesity (BMI 30 or above) only; it is not indicated for the BMI 27–29.9 with comorbidities population and does not apply to the cardiovascular indication. The titration pathway still begins at 0.25 mg; the 7.2 mg level is the eventual maximum for those who reach it under clinical supervision.

For context on how semaglutide compares to other treatment options at this stage of the launch story, the semaglutide treatment page sets out the full picture. If you are also wondering when Wegovy launched and how its rollout has progressed, that page traces the full sequence of approvals and availability. Whether a specific dose or pen format is available through a private provider is confirmed at consultation, no ethical pharmacy commits to stock availability in advance.

Step 3: The oral tablet, a new chapter in the UK launch (June 2026)

The most recent development in the wegovy launch UK timeline is the one that attracted the most attention outside specialist circles. On 11 June 2026, the MHRA approved Wegovy tablets (oral semaglutide formulated with an absorption enhancer) as the first oral GLP-1 medicine licensed for weight management in the UK. The UK was the first country in Europe to grant this authorisation.

The tablet's licensed population is adults with a BMI of 30 or above, or 27 to 29.9 with a weight-related condition. It is not currently available on the NHS; a NICE appraisal would be required before that changes. Evidence came from the OASIS 4 phase 3 trial: across 307 adults with obesity or overweight plus at least one weight-related condition, over 64 weeks, the average weight loss was around 13.6% compared with around 2.4% for placebo. Among participants who remained fully adherent to the treatment schedule, that average reached approximately 16.6%.

The tablet is taken once daily, first thing in the morning on an empty stomach, with no more than a small amount of plain water. Patients must wait at least 30 minutes before eating, drinking anything else or taking other oral medicines. No refrigeration is needed, which makes it more straightforward to manage while travelling. The most common side effects in the trial were gastrointestinal (nausea, vomiting, diarrhoea) reported by around 74% of participants on the active treatment versus 42% on placebo, generally mild to moderate and tending to ease over time.

It is worth noting here that Rybelsus, which is also oral semaglutide, is licensed for type 2 diabetes management and uses a different dose ladder (3 mg, 7 mg, 14 mg). Those strengths are not weight-loss doses and should never be treated as interchangeable with the Wegovy tablet schedule. If you've seen those numbers elsewhere and wondered, the nume FAQs, sorry, the nume FAQs address the distinction directly.

Thinking about whether an oral route might suit you, or whether Wegovy carries any risk of dependence before you commit to a course of treatment? The weight-loss treatment overview outlines the options available through private prescription.

What the launch timeline means for anyone assessing private treatment now

The practical upshot of how the Wegovy launch unfolded is that there are now more licensed options than there were two years ago: the standard injection, the higher-dose pen, and the tablet. None of these is available without a prescription following a clinical assessment. That requirement exists because eligibility depends on your individual health picture, not just your BMI.

For the NHS route, NICE TA875 sets conditions that many people with obesity don't currently meet, and waiting lists for specialist weight management services are commonly long. Private prescribing through a regulated online pharmacy gives access to the same licensed medicine without a referral or a waiting list, provided a prescriber determines it is clinically appropriate for you.

At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber on the same day. Our pharmacy is registered with the GPhC, you can confirm that at registration number 9012878 on the GPhC register. Treatment is priced transparently, one cost covers consultation, prescription, the medicine and free next-working-day delivery through DPD, with no subscription. For background on how our prescribers work, the clinical team page gives the detail.

If you'd like to understand the practicalities of obtaining Wegovy through a legitimate UK route, that page covers what to look for and what to avoid. When you're ready to find out whether treatment is suitable for you, speak to our prescribers through a free consultation.